Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV

Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish investigators report in

Published
17 August 2017
By
Michael Carter
Gilead's hepatitis B therapy to vie with 20 Korean therapies

Korea has approved 20 products made by Korean companies targeting for No.1 chronic hepatitis B therapy Viread (compound: tenofovir disoproxil fumarate) made by Gilead.

Published
14 August 2017
From
Korea Biomedical Review
Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment

For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality rates among people with hepatitis C virus

Published
10 August 2017
By
Michael Carter
UK rations hepatitis B vaccine amid global shortage

Holidaymakers planning to travel abroad from the UK may not be able to get their jab in time, say experts.

Published
08 August 2017
From
BBC Health
AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance

AbbVie could have charged a premium for its broader, faster cure. Its choice to go cheap will make Mavyret a huge bargain relative to Gilead's drugs for many patients. Payers will likely seize on that. The major PBMs have purposefully held off on announcing which HCV drugs they'll cover next year. Gilead will have to offer very large discounts or expect to lose market share.

Published
07 August 2017
From
Bloomberg
European and US regulators approve AbbVie's new combo for all hepatitis C genotypes

The European Commission and the US Food and Drug Administration (FDA) last week approved AbbVie's new combination pill for people with hepatitis C virus (HCV)

Published
07 August 2017
By
Liz Highleyman
Direct-acting antivirals successfully treating hepatitis C, says Public Health England

Public Health England (PHE) is urging the public to get tested for hepatitis C after its latest figures revealed a fall in deaths from the disease, which it attributed to the introduction of direct-acting antiviral (DAA) therapy. PHE’s annual report, published on 28 July 2017, estimated that around 200,000 people in the UK are unknowingly living with chronic hepatitis C, but it said that “revolutionary treatments” can successfully treat the disease in the vast majority of cases, with the best results in the earlier stages of the disease.

Published
02 August 2017
From
Pharmaceutical Journal
Hepatitis B added to routine baby injections

All babies born from Tuesday in England, Wales and Northern Ireland will have an anti-hepatitis B injection added to the other routine vaccinations they are given in their early life. The jab protects against viral infections that cause cirrhosis and liver cancer.

Published
01 August 2017
From
BBC News
Australia leads the world in hepatitis C treatment – what's behind its success?

The key to universal access was the Australian government’s capacity to negotiate much lower drug prices than in other high-income countries, following strong advocacy from the hepatitis C sector. For instance, Australia paid an estimated ten-fold lower price per patient treated in 2016 than did Germany.

Published
31 July 2017
From
The Conversation AU
Substantial fall in Hepatitis C rates in Canberra's jail with new treatments

Justice Minister Shane Rattenbury on Friday released new figures showing how new drugs for the virus had helped reduce the number of Hepatitis C-positive inmates from 30% of the prison population in 2010 down to just three per cent this year.

Published
31 July 2017
From
The Canberra Times
← First12345...225Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.